STF-118804

CAS No. 894187-61-2

STF-118804( STF118804 | STF 118804 )

Catalog No. M17646 CAS No. 894187-61-2

STF-118804 is a highly specific NAMPT inhibitor; reduces the viability of most B-ALL cell lines with IC50 <10 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 50 In Stock
2MG 29 In Stock
5MG 46 In Stock
10MG 70 In Stock
25MG 148 In Stock
50MG 237 In Stock
100MG 352 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    STF-118804
  • Note
    Research use only, not for human use.
  • Brief Description
    STF-118804 is a highly specific NAMPT inhibitor; reduces the viability of most B-ALL cell lines with IC50 <10 nM.
  • Description
    STF-118804 is a potent and highly specific NAMPT inhibitor ( nicotinamide phosphoribosyl transferase inhibitor), which improves survival in an orthotopic xenotransplant model of high-risk acute lymphoblastic leukemia, and targets leukemia stem cells.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    STF118804 | STF 118804
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    NAMPT
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    894187-61-2
  • Formula Weight
    461.53
  • Molecular Formula
    C25H23N3O4S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : ≥ 31 mg/mL; 67.17 mM
  • SMILES
    Cc1ccc(cc1)S(=O)(=O)Cc1c(oc(n1)c1ccc(cc1)C(=O)NCc1cnccc1)C
  • Chemical Name
    4-(5-methyl-4-(tosylmethyl)oxazol-2-yl)-N-(pyridin-3-ylmethyl)benzamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Matheny CJ, et al. Chem Biol. 2013, 20(11), 1352-1363.
molnova catalog
related products
  • p2Ca

    p2Ca, a naturally processed peptide that derives from a ubiquitous enzyme, alpha-ketoglutarate dehydrogenase, and is recognized in association with the class I MHC protein, Ld, by a CTL clone (2C).

  • Luxdegalutamide

    Luxdegalutamide (ARV-766) is a novel, potent, and orally bioavailable proteolytic targeting chimera (PROTAC) protein degrader that degrades not only wild-type AR but also clinically relevant AR LBD mutants, including the most prevalent AR L702H, H875Y, and T878A mutations.

  • TT01001

    TT01001 is a selective agonist of mitoNEET and reduces oxidative stress injury and neuronal apoptosis by improving mitochondrial dysfunction. TT01001 can be used in studies about the treatment of type II diabetes.